surmount-1 trial tirzepatide non-diabetic obesity weight loss once weekly for the treatment of in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 Clinical trials of subcutaneous tirzepatide

Furthermore, we also inform our patients about the financial assistance programs that can help eligible low-income patients afford the cost of tirzepatide

Over time, this becomes automatic, similar to a weekly medication refill or meal prep routine

The dosing protocols differ significantly between the two medications, with tirzepatide starting at 2.5 mg weekly and potentially escalating to 15 mg based on tolerance and response

The FDA's June 29, 2026 comment deadline is real

The stimulant-like mechanism creates dependency risks absent from GLP-1 agonists

For example, a 30 mg vial at the 7.5 mg dose level provides 4 weeks of injections, which aligns perfectly with a 4-week hold at each tapering step